8-K: Charlotte's Web Secures C$103M from BAT, Boosts Stake to 40.8%

Charlotte's Web Holdings, Inc. announced a C$103 million equity commitment from British American Tobacco, significantly increasing BAT's ownership to approximately 40.8% through a new investment and debenture conversion.

Summary

• Charlotte's Web Holdings, Inc. entered into a subscription agreement with BT DE Investments Inc. (BAT), a subsidiary of British American Tobacco p.l.c., on March 30, 2026.
• BAT will purchase US$10,000,000 (approximately C$13.9 million) in Common Shares at a price equal to the greater of C$0.94 per share or a maximum discount to the 5-day volume-weighted average price on the TSX.
• The existing convertible debenture of C$75,341,080 (US$54 million) held by BAT, originally issued on November 14, 2022, will be amended and converted into equity.
• The debenture's conversion price will be amended from C$2.00 to C$0.94 per share, and the interest conversion price will also be C$0.94 per share.
• Immediately following the amendment, BAT will convert the principal and all accrued but unpaid interest on the debenture into 95,281,277 Common Shares.
• The new investment and debenture conversion will result in the issuance of approximately 110 million Common Shares to BAT, representing a total equity commitment of approximately C$103 million (US$75 million).
• Post-transaction, BAT's ownership will increase to approximately 40.8% of the Common Shares, calculated on a non-diluted basis based on 269,725,868 expected outstanding shares.
• An Amended and Restated Investor Rights Agreement will grant BAT the right to nominate directors proportional to its equity ownership (minimum two directors if holding at least 10% equity).
• BAT will also receive demand and piggyback registration rights, pre-emptive rights, top-up rights, and certain minority protections, including approval for significant corporate actions.
• A standstill provision will restrict BAT from acquiring more than 49% of the company's securities or engaging in certain other actions for two years without company consent.
• BAT has agreed to an 18-month lock-up period for its Common Shares, with specified exceptions.
• The transaction requires shareholder approval, with a meeting to be held no later than 70 days from March 30, 2026, and the Board recommending approval.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary capital injection at a lower valuation, providing stability and strategic alignment but at the cost of significant dilution and increased control by a single strategic investor.

Positives

• The company secures important additional capital of approximately C$103 million (US$75 million) at a critical stage in its development.
• The capital infusion is intended to support the company's participation in the Centers for Medicare & Medicaid Services (CMS) Innovation Center (CMMI) program, or its medical channels, and to sustain operations and enterprise value.
• The continued strategic investment from British American Tobacco (BAT) reinforces a key partnership and provides long-term backing.

Negatives

• The conversion price for the C$75,341,080 convertible debenture was significantly reduced from C$2.00 to C$0.94 per share, indicating a lower valuation for the conversion than originally agreed.
• The transaction will result in substantial dilution for existing shareholders, with BAT's ownership increasing from less than 19.9% to approximately 40.8% of the company's common shares.
• The increased ownership and enhanced investor rights for BAT grant it significant control and influence over the company's strategic decisions and corporate governance.

Risks

• The transaction is contingent on obtaining requisite shareholder approval, which, if not secured, could prevent the closing of the investment and debenture conversion.
• Regulatory approvals are required, and failure to obtain them could delay or prevent the consummation of the transactions.
• The company's ability to comply with various laws, including Cannabis Laws, Environmental Laws, Data Protection Laws, Anti-Spam Laws, Money Laundering Laws, and Sanctions, is a continuous operational risk.
• There is a risk of a 'BAT Material Adverse Effect' that could impact BAT's obligations, though this is defined as not arising from BAT's board or senior management decisions.
• The company faces risks related to potential claims, litigation, or regulatory actions if there is any material non-compliance with laws or Cannabis Authorizations.
• The company's internal controls over financial reporting and disclosure controls must remain effective to ensure accurate financial reporting and compliance with securities laws.

Future Outlook

The proceeds from the investment are earmarked to support the company's participation in the Centers for Medicare & Medicaid Services (CMS) Innovation Center (CMMI) program, or alternatively, its medical channels, and to sustain overall business operations and enterprise value. The debenture's interest rate reduction upon federal CBD regulation indicates a strategic alignment with anticipated future regulatory changes in the U.S. CBD market.

Management Comments

• The Investment provides important additional capital at a critical stage in the Company's development.

Industry Context

StockSavvy.ai notes that this significant capital infusion from British American Tobacco underscores the continued strategic interest of major global players in the evolving cannabis and CBD market, particularly as federal regulatory clarity for CBD in food products and dietary supplements in the U.S. remains a key catalyst. The reduced conversion price for the debenture reflects current market valuations for cannabis-related companies, which have faced headwinds and often require capital at lower valuations than previously anticipated.

Comparison to Industry Standards

• StockSavvy.ai observes that a 40.8% ownership stake for a strategic investor like BAT is substantial, approaching a controlling interest, which is higher than typical minority investments seen in the broader consumer goods sector but not uncommon in the nascent and capital-intensive cannabis industry where strategic partnerships often involve significant equity positions.
• The C$0.94 conversion price for the debenture, down from C$2.00, suggests a re-evaluation of the company's valuation, potentially reflecting broader market trends in the CBD sector where valuations have compressed compared to 2022.
• The 18-month lock-up period for BAT's shares is a standard practice for significant equity investments, providing stability post-transaction and signaling long-term commitment, similar to lock-up agreements seen in other strategic investments or IPOs.

Management Changes

Corporate Governance

Related Party Transactions

• The entire transaction, including the new US$10 million equity investment, the amendment and conversion of the C$75.34 million convertible debenture, and the Amended and Restated Investor Rights Agreement, constitutes a significant related-party transaction with BT DE Investments Inc. (BAT), a wholly-owned subsidiary of British American Tobacco p.l.c., which is an existing debenture holder and will become a major equity holder.

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience significant dilution as BAT's ownership increases to approximately 40.8%. However, the capital raise provides financial stability and validates the company's strategic direction through a major investor.
• **Company**: The company receives crucial capital to fund strategic initiatives like the CMMI program and general operations, enhancing its financial health and operational capacity. The partnership with BAT is strengthened, potentially offering strategic advantages.
• **Management/Board**: Management and the Board will operate under increased influence and oversight from BAT, given its substantial equity stake, board nomination rights, and minority protection provisions. This may lead to more structured decision-making processes.
• **Creditors**: The conversion of a significant convertible debenture into equity reduces the company's debt burden, potentially improving its credit profile and financial leverage ratios.

Next Steps

• The company will file a preliminary proxy statement and a definitive proxy statement on Schedule 14A with the SEC.
• The definitive proxy statement and other relevant materials will be mailed or made available to stockholders as of April 6, 2026.
• A special meeting of Company Shareholders will be held no later than 70 days from March 30, 2026, to obtain approval for the transaction resolutions.
• The closing of the Investment is expected to occur on or around May 28, 2026.
• Concurrently with the closing, the company and BAT will enter into an amendment and conversion notice to amend the convertible debenture terms and convert it into Common Shares.
• Concurrently with the closing, the company and BAT will enter into an amended and restated investor rights agreement.

Key Dates

Recommendation

While the capital infusion is crucial for Charlotte's Web, the significant dilution for existing shareholders and the reduced conversion price for the debenture reflect a lower valuation. The increased influence of BAT provides stability but also shifts control. Investors should hold to observe how the new capital is deployed and how the strategic partnership with BAT impacts future growth and profitability, especially given the evolving regulatory landscape for CBD.

Keywords

Charlotte's Web, CWB, British American Tobacco, BAT, Convertible Debenture, Equity Investment, Capital Raise, CBD, Cannabis, SEC Filing, 8-K, Investor Rights, Dilution, Corporate Governance, Strategic Investment